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Abstract 30 
Context: Congenital adrenal hyperplasia (CAH) is lethal in its most severe forms if not treated with 31 
glucocorticoids. However, glucocorticoids may increase the risk of cardiovascular and metabolic 32 
morbidity. 33 
Objective: To study cardiovascular and metabolic morbidity in CAH. 34 
Design, Setting and Participants: Patients with CAH due to 21-hydroxylase deficiency (n=588; 35 
>80% with known CYP21A2 mutations) were compared with controls matched for sex, year, and place 36 
of birth (n=58,800). Data were obtained by linking national population-based registers. Subgroup 37 
analyses were performed regarding sex, clinical severity (salt-wasting, simple virilising, nonclassic), 38 
CYP21A2 genotype (null, I2 splice, I172N, P30L), and stratified by the introduction of neonatal 39 
screening, age-groups, and non-obesity. 40 
Main Outcome Measures: Cardiovascular and metabolic morbidity.  41 
Results: In CAH, both any cardiovascular and metabolic disorders (OR 3.9, 95%CI 3.1-5.0), and 42 
cardiovascular disease (OR 2.7, 95%CI 1.9-3.9) were increased. Separate analyses of the individual 43 
diseases showed higher frequencies in CAH of hypertension, hyperlipidemia, atrial fibrillation, venous 44 
thromboembolism, obesity, diabetes (mainly type 2), obstructive sleep disorder, thyrotoxicosis and 45 
hypothyroidism. Similar results were seen in the stratified groups. On the subgroup level, females 46 
were generally more affected (especially I172N and the nonclassic group), as were males with the null 47 
genotype.  48 
Conclusions: CAH was associated with excess cardiovascular and metabolic morbidity but the 49 
mechanism is not certain as the glucocorticoids were not assessed. Hypothyroidism and obesity may 50 
be an effect of close observation. However, more severe conditions were presumably detected equally 51 
in patients and controls.  Screening for diabetes and other metabolic disorders which increase 52 
cardiovascular risk is important.   53 
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Introduction 54 
Congenital adrenal hyperplasia (CAH) is an autosomal recessive disorder. The most common cause, 55 
21-hydroxylase deficiency, is characterised by a reduction of cortisol and aldosterone production and 56 
concurrently by increased levels of steroid precursors and adrenal androgens (1-3). There is a wide 57 
spectrum of severity of the disease. Untreated CAH is fatal in severe cases due to salt-wasting crises. 58 
Women with classic CAH, i.e., the salt-wasting (SW) or simple virilizing (SV) phenotype, have 59 
varying degrees of virilization of the external genitalia at birth. Individuals with nonclassic (NC) CAH 60 
do not present with cortisol deficiency and may never be diagnosed. If NCCAH is diagnosed, it is 61 
generally due to symptoms and signs of androgen excess, including infertility; therefore, usually more 62 
females rather than males are diagnosed (1, 3).  63 
In most cases, glucocorticoid replacement therapy is necessary for survival in classic CAH. 64 
However, the physiological circadian rhythm of cortisol cannot be mimicked with oral 65 
glucocorticoids, and the doses needed to suppress the androgens are usually higher than normal 66 
replacement (3). Hence, the treatment can be expected to be potentially harmful and may result in an 67 
increased risk of obesity, type 2 diabetes, hyperlipidemia and hypertension, i.e., the metabolic 68 
syndrome, resulting in cardiovascular morbidity and mortality. So far, neither increased cardiovascular 69 
morbidity nor an increased prevalence of type 2 diabetes has been found in CAH patients in the few 70 
studies reporting on cardiovascular morbidity (4, 5). This is to be expected since glucocorticoids were 71 
introduced in the 1950s and very few of the studied patients have been over 50 years of age (3). 72 
However, risk factors for cardiovascular disease and an increased risk for metabolic disorders have 73 
been reported in both children and adults (6-11). We have previously reported an increased risk for 74 
gestational diabetes, a strong risk factor for future type 2 diabetes, in women with CAH (4, 12). In 75 
contrast, we could not demonstrate a significant increase in cardiovascular mortality in CAH 76 
individuals compared to controls (13). Thyroid disease can increase both cardiovascular and metabolic 77 
morbidity (14), but it has not been studied in CAH individuals. 78 
The aims of this study were to investigate the cardiovascular and metabolic morbidity in a 79 
large population-based national cohort of patients with CAH due to 21-hydroxylase deficiency and to 80 
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analyze whether the outcomes varied between the different pheno- and genotype groups, or between 81 
the sexes, as well as stratified by the introduction of neonatal screening, age-groups, and non-obesity. 82 
 83 
Methods 84 
Subjects 85 
CAH patients with 21-hydroxylase deficiency and a complete personal identity number born between 86 
1910 and 2009 were identified (n=545) using the national CAH register (15). More than 80% had the 87 
diagnosis genetically confirmed by CYP21A2 mutation analysis. An additional 43 individuals were 88 
included who had received the diagnosis CAH at least three times in the National Patient Register 89 
(NPR) using the International Classification of Diseases, ICD-8 (255.01, 255.08), ICD-9 (2552, 255C) 90 
and ICD-10 (E25.0) and had not subsequently been given other diagnoses, i.e., Addison’s disease, 91 
Cushing’s syndrome, acromegaly, or received glucocorticoid treatment due to malignancies.  92 
Most patients with known CYP21A2 mutations, analysed as previously described (15, 16), 93 
were allocated to one of the five most prevalent genotype groups (see below). All the different 94 
mutations in this cohort have been described in detail elsewhere (15). The mildest mutation defines the 95 
genotype group in compound heterozygotes. Generally speaking, null and I2 splice are associated with 96 
the SW phenotype, I172N with SV, and V281L with NC. P30L results in a phenotype between SV and 97 
NC, but in this study it was defined as SV. Patients with unknown CYP21A2 mutations were given a 98 
clinical classification (SW, SV or NC) if clinical data that clearly could be used for classification were 99 
accessible. Genetically verified or clinically diagnosed NC disease was combined to the NC group. 100 
The data were also stratified after the introduction of neonatal screening for CAH in Sweden (1986), 101 
three different age groups (0-19, 20-39, and older than 40 years old), and non-obesity. 102 
 103 
Characteristics of the included patients and controls 104 
All CAH patients (n=588, females n=335) had been diagnosed with 21-hydroxylase deficiency. The 105 
median age was 26.0 (range 0–92) years. The clinical phenotype could be determined in 482 patients 106 
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(82.0%). SW, SV and NC phenotypes were diagnosed in 240 (20.7 years, range 0-69), 167 (27.4 years, 107 
range 0.4-79), and 75 (22.1 years, range 3.3-92) patients, respectively. In the most common genotype 108 
groups, the numbers were: null, n=100 (19.4 years, range 0.1-57); I2 splice, n=122 (20.6 years, range 109 
0-69); I172N, n=130 (26.9 years, range 0.7-79); P30L, n=24 (22.4 years, range 0.4–38); and V281L, 110 
n=56 (42 females). A similar number of patients were born before and after the introduction of the 111 
neonatal screening programme, but those born before it were older (before, n=305, 40.3 [15-95] years, 112 
178 females; after, n=283, 14.8 [0–24] years, 157 females). Controls matched for sex, year and place 113 
of birth were included from the Total Population Register (n=58,800). The characteristics of this 114 
cohort have been reported previously (13, 17, 18). 115 
 116 
Study protocol 117 
A matched cohort design was employed, with exposure defined as having the diagnosis CAH in the 118 
national CAH Register or in the NPR. Controls matched for birth year, sex and place of birth were 119 
identified in the Total Population Register (100 controls per CAH individual). The Migration Register 120 
(Statistics Sweden), with all migrations since 1901, was used to control for migration. The Swedish 121 
personal identity number enables unambiguous linkage between population-based registers, including 122 
the NPR (maintained by the Swedish Board of Health and Welfare). All participants in this study were 123 
given an anonymous code number by Statistics Sweden after linkage with the registers. The NPR 124 
contains the discharge diagnoses according to the ICD for both in- and outpatient care since 1964 and 125 
2001, respectively. The outcomes were a diagnosis of cardiovascular or metabolic disorders. The 126 
different ICD codes (Swedish version) used for the separate analyses are shown in Table 1. The study 127 
was approved by the Regional Ethical Review Board in Stockholm, Sweden. 128 
 129 
Statistical analysis 130 
A conditional logistic regression model was used to estimate the association between CAH and the 131 
outcomes in Table 1. The same outcomes were also estimated for the different subgroups. Odds ratios 132 
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(ORs) were calculated with 95% confidence intervals (CIs). A CI not surpassing 1.0 was considered 133 
significant. SAS (version 9.4) was used for all statistical analyses.  134 
 135 
Results 136 
Cardiovascular and metabolic disorders 137 
The results are shown in detail for the total cohort and for males and females in Table 2, broken down 138 
by phenotype group in Table 3 and CYP21A2 genotype group in Table 4 and the number of patients in 139 
each group is shown in Supplemental Table 1.  140 
Any cardiovascular and metabolic disorders were increased in CAH patients, with OR 141 
3.9(3.1–5.0) for the whole cohort, 4.4(3.2–6.0) for females and 3.3(2.3–4.9) for males. The increase 142 
remained significant on the subgroup level for SW (both genders), SV (females), NC (both genders), 143 
null (males), I172N (females) and P30L (males). For cardiovascular disease, the ORs were 2.7(1.9–144 
3.9) for the total CAH cohort and 3.9(2.5–6.1) for females, but were not significant for the males. 145 
They remained significant on the subgroup level for SW (males), SV and NC (females), null (males), 146 
and I172N (females). 147 
Obesity was increased in both genders (OR 10-15[5.5–19.5]) and in all subgroups of patients, 148 
except in I2 splice males and P30L females. Obesity was most pronounced in the NC group (both 149 
genders) and the P30L males. Obstructive sleep apnoea was increased in the entire group (OR 2.0[1.0–150 
4.1]) and in the SV group. In the P30L male group, it almost reached significance. More obese CAH 151 
patients had cardiovascular disease than the non-obese CAH patients (16.3% vs 4.0%, OR 4.6 [1.9–152 
11.5]). Two thirds of the obese CAH patients had uncomplicated obesity and no other cardiovascular 153 
or metabolic disorders. Three CAH patients (one SW, one NC and one with unknown pheno/genotype) 154 
had obesity and five other cardiovascular and metabolic disorders, including type 2 diabetes, 155 
hypertension, and acute coronary syndrome or stroke. One CAH patient had obesity combined with 156 
hypertension and hypothyroidism while five had obesity combined with hypertension, 157 
hyperlipidaemia, or venous thromboembolism. The obese patients with CAH are described in detail in 158 
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Supplemental Table 2. Moreover, if only the non-obese CAH patients were compared to their non-159 
obese controls the results were similar to the entire cohort (Table 7). 160 
Diabetes was more prevalent in the entire cohort and among females (OR 3.0[1.6-5.8] and 161 
4.0[1.8–9.1], respectively) compared to controls. The rate in the subgroups was elevated among 162 
females in the SV, NC and I172N groups.  163 
Hypertension occurred more often in females (OR 4.1[2.4–7.3]) and remained significant only 164 
for SV and I172N females. The rate of hyperlipidaemia was increased in the total cohort (OR 2.8[1.2–165 
6.5]) and in the SW and null (males) subgroups. The frequency of stroke was elevated in only the NC 166 
female group. 167 
Venous thromboembolic events were raised in the entire cohort (OR 3.8 [1.6–8.7]) and SW, 168 
NC, null and I2 splice subgroups. Mostly CAH females were affected.  169 
Acute coronary syndrome was only increased in SW (males) and null (males) groups. Cardiac 170 
arrest and heart failure were similar to the findings in controls in all groups. Atrial fibrillation was 171 
more frequent in the total cohort (OR 2.3[1.0–5.2]), but was not significant at the subgroup level, 172 
except in I172N males. The prevalence of heart block and aortic valve disease was similar to that in 173 
controls. One case of cardiomyopathy (SW female, null genotype) and one case of pulmonary heart 174 
disease (SW female), but no cases of aortic aneurysm and dissection were found in the CAH cohort 175 
(all non-significant compared to controls). 176 
Thyroid disease was increased in both males and females. Thyrotoxicosis and hypothyroidism 177 
were increased (OR 4.7[2.4–8.9] and 3.7[2.2–6.3]), being most pronounced in males (OR 15.8[4.7–178 
53.4] and 12.9[5.8–28.7]). In a subgroup analysis, thyrotoxicosis was more frequent in SW (males), 179 
NC (both genders) and null (males) subgroups. In the subgroup of hypothyroidism only males in SW, 180 
SV, NC, null and I172N groups were affected. 181 
Patients born before the introduction of neonatal screening showed similar results to those in 182 
the entire cohort (data not shown), but those born after 1986, showed an increased frequency of any 183 
cardiovascular and metabolic disorders, obesity, hypertension and thyrotoxicosis (data not shown). 184 
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Compared to controls, those born after the introduction of neonatal screening had higher risk (0.34% 185 
vs 0.04%, OR 7.5[1.7–32.9]) of having hypertension compared to those born before (3.6% vs 1.8%, 186 
OR 1.5[1.0–2.4]). Moreover, when the cohort was stratified into different age groups, the CAH 187 
patients in 0-19 year-old group were mainly affected by obesity and thyrotoxicosis, but females had 188 
more hypertension and males hypothyroidism compared to controls. The older groups of CAH patients 189 
also had more cardiovascular disease compared to controls (Table 5).   190 
   191 
Discussion 192 
This is the first time established cardiovascular disease, and not merely risk factors, have been 193 
investigated in a large cohort of CAH patients. We found increased cardiovascular and metabolic 194 
morbidity in CAH patients compared to controls with some subgroups being more affected than others 195 
(females generally, and specifically I172N and NC, and males in the null genotype group). Obesity 196 
was consistently increased in all subgroups with the NC group and P30L males being most affected. 197 
Even though all the separate measured outcomes, except aortic aneurysm, were increased in 198 
CAH individuals, some did not reach statistical significance, probably owing to a lack of statistical 199 
power. Although this is the largest CAH cohort ever reported, the median age was relatively low and 200 
cardiovascular disease occurs more commonly at an older age. Moreover, in the general population, 201 
cardiovascular disease is more prevalent in males, which has been attributed to the higher testosterone 202 
levels compared to females. CAH results in elevated androgens, and it could be speculated that this is 203 
one of the reasons for the increased cardiovascular morbidity demonstrated in this study, illustrated by 204 
the NC group being especially affected. Delayed diagnosis, which is frequently seen in the milder 205 
pheno- and genotypes and especially before the introduction of neonatal screening, is frequent and 206 
results in prolonged hyperandrogenism. However, once treatment with glucocorticoids has been 207 
initiated, androgens are usually decreased compared to controls (4, 19).  208 
Obesity was markedly increased, which is consistent with many studies reporting an increased 209 
body mass index and/or fat mass in CAH children and adults (4, 5, 8, 11, 20-24). NC individuals and 210 
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P30L males were most affected by obesity. However, only a minority of the obese CAH patients had 211 
been diagnosed with another cardiovascular or metabolic disorder and the non-obese CAH patients 212 
were similarly affected as the entire CAH cohort. Obstructive sleep apnoea is prevalent in obesity, but 213 
it has only been reported once in a case of CAH (25), although it could be suspected to occur more 214 
frequently. However, we did find an increased frequency of obstructive sleep apnoea in this CAH 215 
cohort. Similarly, the frequency of diabetes was increased, especially in females with SV (I172N 216 
genotype) or NC phenotype. Decreased insulin sensitivity in CAH children and adults has been 217 
reported several times previously (4-6, 9, 23, 26); however, this is the first time a raised occurrence of 218 
diabetes has been found. Interestingly, Williams et al. reported insulin resistance only in NC but not in 219 
classic CAH children (26), and in a Chinese study on newly diagnosed and untreated young adult 220 
females with SV, insulin resistance was found. It has also been claimed that  androgens in females can 221 
result in insulin resistance (27). Thus, all this taken together could suggest that prolonged postnatal 222 
hyperandrogenism, and not only supraphysiological glucocorticoid replacement therapy together with 223 
obesity, may cause insulin resistance and diabetes in CAH patients. The doses of corticosteroids used 224 
are usually similar in the different pheno- and genotypes (5, 19, 28), and it can be speculated that a 225 
more unfavourable profile could be explained by a relative overtreatment considering the milder 226 
disease. However, doses of corticosteroids are usually those reported only at the time of the study and 227 
the cumulative dose during the entire treatment period is generally unknown. As CAH females have 228 
more symptoms of hyperandrogenism compared to CAH males, the females may have been exposed 229 
to higher doses of corticosteroids, especially during younger ages, which may explain why females 230 
were more affected. 231 
An increased rate of hyperlipidaemia was found, especially in our males with null genotype. 232 
Hyperlipidaemia in CAH individuals has been reported in some studies (8, 22), yet, most have found 233 
similar lipid profiles, compared to controls (4-6, 11, 26, 29). We found an increased frequency of 234 
hypertension in CAH individuals, which is similar to other studies (8, 11, 22, 26, 29), but on analysing 235 
the different subgroups, only SV (I172N) females and NC females (tendency) had increased blood 236 
pressures, while this was rare or non-existent in the more severe pheno- and genotypes. Most previous 237 
studies have not compared the results in different pheno-and genotypes; however, a few have indicated 238 
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a higher blood pressure in patients with milder forms of CAH, i.e., I172N and NC groups (5, 26). 239 
Moreover, classic adult CAH males were recently reported to have lower blood pressure compared to 240 
healthy men (24). Mineralocorticoid replacement is generally mandatory in SW and is often 241 
recommended in SV cases to minimise the glucocorticoid doses (1-3), and it is sometimes used even 242 
in NC patients (4, 5, 8, 26). A more cautious approach to prescribing mineralocorticoids could 243 
possibly be employed, but this has to be investigated in studies where the prescribed doses of 244 
mineralocorticoids are known and, ultimately, in randomised controlled trials. Obesity was more 245 
pronounced among patients with the milder forms and this may contribute to the development of 246 
hypertension. One of the main risks of hypertension is stroke, and we did find an increased occurrence 247 
of stroke in the NC female group, but not in the other groups. It has been demonstrated that patients 248 
with classic CAH and severe mutations have reduced epinephrine production (null and I2splice), 249 
whereas those carrying the milder I172N had normal production (1, 5). It could be speculated that not 250 
only a later diagnosis of CAH (5, 26), but also differences in epinephrine secretion, could influence 251 
the cardiovascular risk profiles (5). 252 
Another risk factor for stroke, atrial fibrillation, was increased in CAH individuals and in the 253 
I172N group, but this time only in males. Atrial fibrillation has never been studied in CAH before, but 254 
heart rates have been reported to be elevated (5, 29). Alcohol can precipitate atrial fibrillation and 255 
alcohol misuse was increased in these CAH males, as reported previously by our group (17); however, 256 
this was only significant in the I2 splice group. Thyrotoxicosis can also predispose to atrial fibrillation, 257 
and this risk was increased in CAH individuals. The frequency of thyrotoxicosis was extremely high 258 
compared to controls in null and NC males, while being only moderately raised in NC females. The 259 
prevalence of hypothyroidism was also elevated, especially in the male subgroups. However, thyroid 260 
disorders are generally more common in females, which may explain the lower OR in CAH females. 261 
Thyroid disorders have not been studied before in CAH. The main cause of both hyper- and 262 
hypothyroidism is autoimmunity and the question arises of whether there is an increased risk for 263 
autoimmune disorders in CAH. The gene responsible for the 21-hydroxylase enzyme, CYP21A2, and 264 
its pseudogene, CYP21A1P, is located in the HLA major histocompatibility complex on chromosome 265 
6p21.3, about 30 kb apart, next to the C4B and C4A genes, but there are also other genes involved in 266 
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the immune system located in the vicinity (30). A putative link is purely speculative but should be 267 
studied further.  268 
We were able to show for the first time an increased frequency of venous thromboembolic 269 
events in CAH individuals. This could be expected, as both Cushing’s syndrome and glucocorticoid 270 
use have been associated with venous thromboembolism due to a state of hypercoagulability (31). 271 
More liberal use of thrombosis prophylaxis may be warranted.  272 
Patients born after the introduction of neonatal CAH screening seemed to be less affected than 273 
those born before, which may indicate a benefit of early diagnosis and/or more optimal corticosteroid 274 
replacement therapy in recent years. However, there was a difference in mean age of almost 26 years 275 
between the two groups. When stratifying the cohort into different age groups, all age groups were 276 
equally affected by any cardiovascular and metabolic disorder. However, the older age groups also had 277 
an increased risk of cardiovascular disease while the younger mainly were affected by obesity and 278 
thyrotoxicosis; females also had more hypertension and males hypothyroidism compared to controls.  279 
The major limitations of this study are that all outcome data were derived from national 280 
registers, and the ICD coding may have been inadequate. A prerequisite for obtaining approval by the 281 
Ethics Committee was that all individuals included were anonymised to protect their privacy. 282 
Therefore, it was impossible to analyse the results on an individual level and compare them with 283 
medical files. There may be ascertainment bias as the CAH patients were more likely to be under 284 
intensive surveillance compared to controls, which may explain some of the differences, e.g. the 285 
observation of hypothyroidism and obesity. However, more severe conditions were presumably 286 
detected equally in patients and controls. Moreover, the number of patients with cardiovascular 287 
disease was low, in spite of the large number of included individuals with CAH due to the low median 288 
age of only 26 years, considering that most cardiovascular events occur in the middle and older age 289 
groups. Furthermore, the number of patients in the different severity subgroups was low and some of 290 
the ICD codes were used only occasionally. Moreover, the many different subgroup analyses 291 
performed will, by definition, give rise to some significant results by sheer chance. Hence, the results 292 
from the subgroup analysis must be interpreted with caution. However, the present study probably 293 
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underestimates the cardiovascular morbidity among patients with CAH as we have recently shown 294 
from the same cohort that this group died 6.5 years earlier compared to controls, mainly due to adrenal 295 
crisis (13). Thus, the CAH patients have not had the same risk of developing cardiovascular disease. In 296 
contrast, the strengths of this study are the unique national registry of CAH individuals covering 297 
almost all CAH patients diagnosed in Sweden, with most registered patients being both pheno- and 298 
genotyped, and the almost complete coverage of all discharge diagnoses according to ICD of both in- 299 
and outpatient care by the National Patient Register.  300 
In conclusion, CAH was associated with excess cardiovascular and metabolic morbidity. Some 301 
subgroups seemed to be more affected. Regular follow-up is needed with lifestyle intervention to limit 302 
the onset of weight gain and obesity, screening for diabetes, other metabolic disorders and 303 
cardiovascular risk factor. Close monitoring of glucocorticoid doses is important. 304 
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Table 1. The discharge diagnoses from the National Patient Registry analysed according to ICDs for 
both in- and outpatient care.  
 Diagnosis ICD 8 ICD 9 ICD 10 
1 Obesity 277 278 E66 
2 Diabetes mellitus 250 250 E10, E11, E13 
3 Type 1 and type 2 diabetes   E10 & E11 
4 OSA  347.00, 780.60 347, 780F G47 
5 Hyperlipidaemia 272 272 E78 
6 Hypertension 401 401, 405 I10, I15 
7 Stroke
$
 430-436 430-436 I60-I64, G45 
8 ACS 410,411 410,411 I20-I22 
9 Cardiac arrest 427.98 427F I46 
10 Heart failure 427.00, 427.10 428 I50 
11 Atrial fibrillation*  427.92 427D I48 
12 Heart block 427.20, 427.28 426 I44, I45 
13 Aortic valve disease** 395 424B I35 
14 VTE 450, 451 415, 451 I26, I80 
15 Cardiomyopathy 425 425 I42 
16 Aortic aneurysm & dissection 441 441 I71 
17 Pulmonary heart diseases 426 416 I27 
18 Hypotension 458 458 I95 
19 Thyrotoxicosis 242 242 E05 
20 Hypothyroidism 244, 245 244, 245 E03, E06 
*includes atrial flutter. **non-rheumatic.
 $
includes transient cerebral ischaemic attack. ACS, acute 
coronary syndrome, i.e. heart attack and unstable angina. VTE, venous thromboembolism. OSA, 
obstructive sleep apnoea, but also includes other occasional sleep disorders. Any cardiovascular and/or 
metabolic disorder was defined as no. 1–20, and any cardiovascular disease as no. 6–18. 
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Table 2. Cardiovascular and metabolic disorders in CAH individuals with 21-hydroxylase deficiency, also divided into females and males, compared with age- 
and sex-matched controls (100 controls per case). 
 
CAH 
individuals 
Controls Odds ratio  
(95% CI) 
CAH 
females 
Controls 
females 
Odds ratio  
(95% CI) 
CAH 
males 
Controls 
males 
Odds ratio  
(95% CI) 
n 588 58 800  335 33 500  253 25 300  
Any CVD & meta 99(16.8%) 3460(5.9%) 3.9(3.1-5.0) 62(18.5%) 3460(5.9%) 4.4(3.2-6.0) 37(14.6%) 1496(5.9%) 3.3(2.3-4.9) 
Any CVD 44(7.5%)  2103(3.6%) 2.7(1.9-3.9) 30(9.0%) 1109(3.3%) 3.9(2.5-6.1) 14(5.5%) 1008(3.9%) 1.6(0.9-2.9) 
Obesity 29(4.9%) 281(0.5%) 10.9(7.4-16.2) 18(5.4%) 170(0.5%) 11.3(6.8-18.7) 11(4.3%) 111(0.4%) 10.4(5.5-19.5) 
Diabetes 16(2.7%) 741(1.3%) 3·0(1.6-5.8) 10(3.0%) 375(1.1%) 4.0(1.8-9.1) 6(2.4%) 366(1.4%) 2.1(0.7-6.1) 
OSA 8(1.4%) 406(0.7%) 2.0(1.0-4.1) 3(0.9%) 154(0.5%) 2.0(0.6-6.2) 5(2.0%) 252(1.0%) 2.0(0.8-5.0) 
Hyperlipidaemia 6(1.0%) 230(0.4%) 2.8(1.2-6.5) 3(0.9%) 110(0.3%) 2.9(0.9-9.5) 3(1.2%) 120(0.5%) 2.7(0.8-8.8) 
Hypertension 23(3.9%) 1058(1.8%) 2.6(1.6-4.2) 18(5.4%) 582(1.7%) 4.1(2.4-7.3) 5(2.0%) 477(1.9%) 1.1(0.4-2.7) 
Stroke
$ 5(0.9%) 423(0.7%) 1.2(0.5-3.1) 4(1.2%) 253(0.8%) 1.7(0.6-4.9) 1(0.4%) 170(0.7%) 0.6(0.1-4.3) 
ACS 6(1.0%) 436(0.7%) 1.5(0.6-3.5) 2(0.6%) 198(0.6%) 1.0(0.2-4.4) 4(1.6%) 238(0.9%) 1.9(0.6-5.7) 
Cardiac arrest 1(0.2%) 35(0.1%) 2.8(0.4-21.0) 0(0%) 17(0.1%)  1(0.4%) 18(0.1%) 5.6(0.7-42.0) 
Heart failure 3(0.5%) 209(0.4%) 1.5(0.4-5.1) 2(0.6%) 109(0.3%) 2.0(0.4-9.3) 1(0.4%) 100(0.4%) 1.0(0.1-7.9) 
Atrial fibrillation* 7(1.2%) 331(0.6%) 2.3(1.0-5.2) 3(0.9%) 156(0.5%) 2.1(0.6-7.1) 4(1.6%) 175(0.7%) 2.5(0.9-7.4) 
Heart block 3(0.5%) 120(0.2%) 2.5(0.8-8.0) 1(0.3%) 56(0.2%) 1.8(0.2-13.1) 2(0.8%) 64(0.3%) 3.2(0.8-13.0) 
Aortic valve dis** 2(0.3%) 101(0.2%) 2.0(0.5-8.3) 1(0.3%) 52(0.2%) 1.0(0.3-14.7) 1(0.4%) 49(0.2%) 2.1(0.3-15.4) 
VTE 6(1.0%) 165(0.3%) 3.8(1.6-8.7) 5(1.5%) 106(0.3%) 5.0(2.0-12.7) 1(0.4%) 59(0.2%) 1.7(0.2-12.4) 
Thyrotoxicosis 10(1.7%) 223(0.4%) 4.7(2.4-8.9) 7(2.1%) 204(0.6%) 3.5(1.6-7.6) 3(1.2%) 19(0.1%) 15.8(4.7-53.4) 
Hypothyroidism 15(2.6%) 418(0.7%) 3.7(2.2-6.3) 8(2.4%) 362(1.1%) 2.3(1.1-4.6) 7(2.8%) 56(0.2%) 12.9(5.8-28.7) 
CI, confidence interval. 
$
Includes transient cerebral ischaemic attack. *Includes atrial flutter. **Non-rheumatic. CVD, cardiovascular disease. meta, metabolic 
disorder. OSA, obstructive sleep apnoea. ACS, acute coronary syndrome, i.e., heart attack and unstable angina. VTE, venous thromboembolism. Bold, P<0.05. 
Italic, P=0.05–0.09. No odds ratio and CI are calculated when no patient had the condition. 
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Table 3. Cardiovascular and metabolic disorders in CAH individuals with 21-hydroxylase deficiency divided into the three phenotypes, compared with age- and 
sex-matched controls (100 controls per case). 
 SW SV NC 
 
Odds ratio 
(95% CI) 
Odds ratio 
(95% CI) 
Odds ratio 
(95% CI) 
Odds ratio 
(95% CI) 
Odds ratio 
(95% CI) 
Odds ratio 
(95% CI) 
Odds ratio 
(95% CI) 
Odds ratio 
(95% CI) 
Odds ratio 
(95% CI) 
 All Females Males All Females Males All Females Males 
n 240 135 105 167 91 76 75 56 19 
Any CVD & meta 3.2(2.1-4.9) 2.4(1.3-4.5) 4.4(2.4-8.0) 2.9(1.8-4.6) 3.9(2.1-7.0) 1.9(0.9-4.0) 5.6(2.9-10.8) 5.9(2.9-12.3) 4.5(1.0-21.0) 
Any CVD 2.7(1.4-5.3) 2.1(0.8-6.0) 3.4(1.4-8.2) 1.8(0.9-3.5) 3.3(1.5-7.6) 0.9(0.3-2.5) 2.9(1.0-8.3) 3.7(1.2-11.2)  
Obesity 10.9(5.8-20.7) 8.6(3.4-21.8) 14.1(5.8-34.4) 6.9(3.0-16.0) 5.9(1.8-19.3) 8.3(2.5-27.3) 17.1(5.7-51.8) 15.3(4.3-54.9) 25.0(2.8-224) 
Diabetes 1.8(0.2-13.2)  3.2(0.4-24.2) 3.1(1.2-8.4) 6.2(1.8-21.5) 1.6(0.4-7.5) 4.1(1.2-13.7) 5.5(1.6-19.3)  
OSA 0.8(0.1-5.8) 2.0(0.3-14.7)  2.8(1.0-7.6) 2.2(0.3-16.3) 3.0(0.9-9.7) 2.6(0.4-19.2) 3.3(0.4-24.7)  
Hyperlipidaemia 6.2(1.4-27.3)  11.1(2.3-53.2) 1.6(0.4-6.7) 2.2(0.3-16.7) 1.3(0.2-9.8)    
Hypertension 1.2(0.3-4.9)  2.6(0.6-11.2) 1.7(0.7-3.9) 5.0(1.9-13.1) 0.3(0.0-2.2) 2.8(0.8-10.5) 3.2(0.8-12.6)  
Stroke
$
    0.5(0.1-3.8)  0.8(0.1-6.3) 5.8(1.1-30.8) 5.8(1.1-30.8)  
ACS 5.3(1.2-24.3)  9.9(2.0-50.1) 1.4(0.4-4.9) 2.4(0.3-19.7) 1.1(0.2-5.2)    
Heart failure    2.3(0.5-10.8) 6.3(0.8-48.4) 1.3(0.2-10.9) 8.0(0.7-92.8) 9.1(0.7-114)  
Atrial fibrillation* 2.3(0.3-17.4)  3.8(0.5-29.6) 2.3(0.7-8.2)  3.1(0.8-11.6) 3.6(0.4-30.5) 4.3(0.5-38.5)  
Heart block    3.9(0.9-16.4) 4.7(0.6-35.5) 3.4(0.5-25.3)    
VTE 10.5(3.1-35.3) 13.1(2.9-58.9) 7.4(0.9-59.0)    7.0(0.9-55.5) 8.9(1.1-74.7)  
Thyrotoxicosis 4.5(1.4-14.5) 1.6(0.2-11.7) 33.3(6.7-165)    12.3(4.1-36.9) 8.9(2.6-30.8) 326(12.8->1000) 
Hypothyroidism 2.2(0.7-7.1) 0.9(0.1-6.3) 8.7(2.1-37.3) 3.4(1.2-9.3) 1.9(0.5-8.0) 11.9(2.6-53.7) 5.7(1.7-19.0) 3.7(0.9-16.5) 50.0(4.5-551) 
CI, confidence interval. 
$
Includes transient cerebral ischaemic attack. *Includes atrial flutter. CVD, cardiovascular disease. meta, metabolic disorder. OSA, 
obstructive sleep apnoea. ACS, acute coronary syndrome, i.e. heart attack and unstable angina. VTE, venous thromboembolism. Bold, P<0.05. Italic, P=0.05-
0.07. No odds ratio and CI were calculated when no patient had the condition. 
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Table 4. Cardiovascular and metabolic disorders in CAH individuals constituting the four most common CYP21A2 genotype groups compared with age- and 
sex-matched controls (100 controls per case). Severity of the genotype ranging from left to right.  
 Null I2 splice I172N 
 
Odds ratio 
(95% CI) 
All 
Odds ratio 
(95% CI) 
Females 
Odds ratio 
(95% CI) 
Males 
Odds ratio 
(95% CI) 
All 
Odds ratio 
(95% CI) 
Females 
Odds ratio 
(95% CI) 
Males 
Odds ratio 
(95% CI) 
All 
Odds ratio 
(95% CI) 
Females 
Odds ratio 
(95% CI) 
Males 
n 100 59 41 122 67 55 130 72 58 
Any CVD & meta 5.1(2.8-9.5) 2.4(0.8-6.8) 10.9(4.8-24.7) 1.9(0.9-3.8) 2.3(0.9-5.8) 1.4(0.4-4.7) 3.4(2.1-5.6) 4.9(2.6-9.0) 1.9(0.8-4.5) 
Any CVD 4.9(1.9-13.1) 2.0(0.3-14.6) 8.9(2.7-29.3) 1.3(0.4-4.1) 1.6(0.4-6.8) 0.8(0.1-6.9) 2.2(1.1-4.4) 3.8(1.6-8.8) 1.1(0.4-3.4) 
Obesity 10.1(4.0-26.2) 6.5(1.5-27.9) 16.3(4.6-58.0) 8.2(2.9-23.3) 11.7(3.4-39.8) 4.3(0.6-32.8) 7.0(2.8-17.6) 7.0(2.1-23.1) 7.1(1.7-30.1) 
Diabetes    1.1(0.1-7.7)  2.3(0.3-16.8) 3.7(1.4-10.2) 7.1(2.0-25.0) 2.0(0.4-9.3) 
OSA 1.9(0.3-14.3) 4.8(0.6-36.2)     2.7(0.8-8.6) 2.8(0.4-21.1) 2.6(0.6-10.9) 
Hyperlipidaemia 11.1(1.3-97.5)  18.1(1.7-188)    1.9(0.4-8.0) 2.3(0.3-18.2) 1.6(0.2-12.1) 
Hypertension 1.9(0.3-14.7)  3.5(0.4-29.1)    2.0(0.9-4.7) 5.5(2.1-14.7) 0.3(0.0-2.7) 
Stroke
$
       0.5(0.1-4.1)  0.8(0.1-7.1) 
ACS 18.1(1.7-188)  34.6(2.1-579)    1.6(0.5-5.8) 2.4(0.3-19.7) 1.4(0.3-6.5) 
Heart failure       2.6(0.6-12.3) 6·8(0.9-52.0) 1.5(0.2-12.6) 
Atrial fibrillation*    3.3(0.4-25.6)  6.1(0.7-50.8) 2.7(0.8-9.5)  3.8(1.0-14.4) 
Heart block       4.7(1.1-19.7) 5.4(0.7-42.2) 4.1(0.5-31.1) 
VTE 10.5(1.3-86.6)  18.2(2.0-167) 12.5(2.8-56.6) 21.6(4.5-104)     
Thyrotoxicosis 8.8(2.0-39.0)  200(18.1->1000) 2.7(0.4-20.5) 2.9(0.4-21.8)     
Hypothyroidism 2.0(0.3-14.9)  14.3(1.8-116)    4.2(1.5-11.8) 2.5(0.6-10.3) 13.6(2.9-62.9) 
P30L males with odds ratio (95% CI): Any CV & metab 7.1(1.5-34.8); obesity 7.1(1.5-34.8); and OSA 7.6(0.9-63). Women with P30L genotype had none of the 
studied disorders. CI, confidence interval. 
$
Includes transient cerebral ischaemic attack. *Includes atrial flutter. CVD, cardiovascular. meta, metabolic disorder. 
OSA, obstructive sleep apnoea. ACS, acute coronary syndrome, i.e., heart attack and unstable angina. VTE, venous thromboembolism. Bold, P<0.05. Italic, 
P=0.05-0.07. No odds ratio and CI were calculated when no patient had the condition.
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Table 5. Cardiovascular and metabolic disorders in CAH individuals with 21-hydroxylase deficiency in different age groups, also divided into females and 
males, compared with their age- and sex-matched controls. 
 0-19 years old 20-39 years old 40-92 years old 
 
Odds ratio 
(95% CI) 
All 
Odds ratio 
(95% CI) 
Females 
Odds ratio 
(95% CI) 
Males 
Odds ratio 
(95% CI) 
All 
Odds ratio 
(95% CI) 
Females 
Odds ratio 
(95% CI) 
Males 
Odds ratio 
(95% CI) 
All 
Odds ratio 
(95% CI) 
Females 
Odds ratio 
(95% CI) 
Males 
n 228 122 106 239 143 96 121 70 51 
Any CVD & meta 4.2(2.4-7.1) 3.7(1.7-8.1) 4.6(2.2-9.6) 3.7(2.5-5.4) 4.2(2.6-6.6) 3.0(1.5-5.8) 3.9(2.6-5.8) 4.9(2.9-8.3) 2.7(1.4-5·2) 
Any CVD  2.2(0.5-10.2) 2.9(0.4-21.6) 1.7(0.2-15.9) 3.8(2.1-6.8) 6.0(3.1-11.5) 1.3(0.3-5.3) 2.2(1.4-3.6) 3.0(1.6-5.5) 1.4(0.6-3.1) 
Obesity 12.6(6.4-24.8) 11.1(3.8-32.0) 13.9(5.8-33.4) 9.8(4.9-19.7) 9.3(3.9-21.8) 11.0(3.3-36.9) 11.3(5.8-22.3) 14.0(6.5-30.5) 6.5(1.5-27.7) 
Diabetes 2.3(0.6-9.2) 2.1(0.3-15.3) 2.5(0.3-18.0) 1.4(0.4-4.4) 2.5(0.8-8.3)  2.9(1.5-5.6) 3.1(1.3-7.5) 2.7(1.0-7.1) 
OSA    1.6(0.4-6.4) 1.8(0.3-13.3)  3.5(1.5-8.0) 3.5(0.8-14.7) 3.5(1.2-9.8) 
Hyperlipidaemia       2.6(1.0-6.5) 2.1(0.5-8.5) 3.0(0.9-10.2) 
Hypertension 6.7(0.9-50.5) 10.0(1.3-78.1)  5.3(2.4-11.8) 8.6(3.5-20.8)  1.9(1.0-3.4) 2.7(1.3-5.4) 1.0(0.3-3.0) 
Stroke
$
       1.1(0.4-3.2) 1.0(0.2-4.5) 0.6(0.1-5.0) 
ACS       1.5(0.6-3.6) 2.4(0.3-19.7) 1.4(0.3-6.5) 
Cardiac arrest       3.7(0.5-27.9)  8.3(1.1-64.9) 
Heart failure       1.8(0.6-6.1) 2.3(0.5-11.0) 1.2(0.1-9.8) 
Atrial fibrillation*    2.7(0.4-19.6)  4.1(0.6-30.8) 2.1(0.8-5.4) 2.6(0.7-9.3) 3.8(1.0-14.4) 
Heart block 3.1(0.3-37.6)  3.7(0.3-49.2)    3.0(0.7-12.6) 3.2(0.4-23.8) 2.9(0.4-21.9) 
Aortic valve dis**       2.9(0.7-12.2) 2.7(0.4-21.2) 3.0(0.4-23.1) 
VTE    2.4(0.3-17.6) 3.7(0.5-27.2)  4.6(1.8-11.5) 6.0(2.1-17.4) 2.4(0.3-17.7) 
Thyrotoxicosis 28.6(5.9-138) 14.3(1.8-116) 201(18.0->1000) 5.1(2.0-12.6) 3.4(1.1-11.0) 16.4(3.7-73.4) 2.8(0.9-9.0) 2.9(0.9-9.5)  
Hypothyroidism 2.1(0.5-9.6)  7.6(1.4-43.1) 3.4(1.5-7.7) 3.1(1.3-7.7) 5.4(0.7-40.7) 4.8(2.2-10.6) 2.2(0.7-7.1) 26.9(8.4-86.1) 
CI, confidence interval. 
$
Includes transient cerebral ischaemic attack. *Includes atrial flutter. **Non-rheumatic. CVD, cardiovascular disease. meta, metabolic 
disorder. OSA, obstructive sleep apnoea. ACS, acute coronary syndrome, i.e., heart attack and unstable angina. VTE, venous thromboembolism. Bold, P<0.05. 
Italic, P=0.05-0.07. No odds ratio and CI were calculated when no patient had the condition.
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